GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

GSK plcNYSE: GSK

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes growth accelerates

Q2 FY2026 effect of forex changes of £63.79M (cash outflow) rose 145.3% year over year, ahead of the +74.1% change in trailing-twelve-month effect of forex changes. Over 3 fiscal years it compounded at -62.8% a year.

Context

  • Effect of forex changes amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +145.3% holds above the trailing-twelve-month pace of +74.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-£63.79M-3289.5% QoQ
Last fiscal yearDec 2025
-£32.94M-39.0% YoY
LTMJun 2026
-£111.42M+74.1% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+145.3%——
1 year-39.0%——
3-year CAGR-62.8%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

GBP · from the cash flow

Latest · FY2025
(32.94M) GBP
Year-over-year change
+39.0%

Effect of Forex Changes vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +74.1% is the 4th highest of 9, against a peer median of -59.4%.
  • Effect of forex changes amounts to 0.3% of revenue for GSK, versus a peer median of 0.0%.
GSK Competitors
Effect of Forex Changes for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNYSanofiLTM Jun 2026€142.06M EUR+810.3%+375.9%0.3%
GSKGSK plcLTM Jun 2026£111.42M GBP+74.1%-62.8%0.3%
NVSNovartis AGLTM Jun 2026$103.32M USD-124.4%—0.2%
NVONovo Nordisk A/SLTM Jun 2026DKK 55M DKK-89.6%+45.1%0.0%
AZNAstraZeneca PLCLTM Sep 2026$37.86M USD+262.5%—0.1%
MRKMerck & Co., Inc.LTM Jun 2026$33M USD-92.8%—0.0%
LLYEli Lilly and CompanyLTM Jun 2026$20.4M USD-109.9%—0.0%
PFEPfizer Inc.LTM Jun 2026$17M USD-29.2%—0.0%
JNJJohnson & JohnsonLTM Sep 2026$13M USD+165.0%—0.0%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding GSK) —-59.4%+210.5%0.0%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.52B5.49B6.13B2.95B5.59B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
Deferred Income Tax0(965.72M)(1.08B)00
Stock-Based Compensation343M00344M0
Change in Working Capital1.39B(1.67B)(1.06B)2.09B(608.37M)
Accounts Receivables(1.16B)(758.78M)(806.74M)340M0
Inventory51M(331.35M)(527.05M)(294M)0
Accounts Payables0608.5M(18.65M)00
Other Working Capital2.5B(1.19B)288.39M2.04B(608.37M)
Other Non-Cash Items584M3.16B1.61B(1.38B)(153.41M)
Operating Cash Flow7.95B8.16B7.89B6.55B7.14B
Capital Expenditures(2.65B)(1.41B)(1.63B)(2.98B)(1.32B)
Acquisitions (Net)185M(3.79B)(1.72B)1.37B(4.37B)
Purchases of Investments0(177.38M)(152.9M)0(89.98M)
Sales of Investments18M294.4M2.37B21M195.62M
Other Investing Activities(1.03B)(4.43B)14.92M(1.22B)1.46B
Investing Cash Flow(1.78B)(10.88B)(2.4B)(1.23B)(5.72B)
Debt Repayment(2B)(5.69B)(2.95B)(1.17B)1.47B
Common Stock Issued21M30.79M12.43M20M14.67M
Common Stock Repurchased00000
Dividends Paid(4B)(4.27B)(2.79B)(2.44B)(2.51B)
Other Financing Activities(1.61B)11.98B(341.84M)(1.14B)(573.16M)
Financing Cash Flow(7.59B)2.05B(6.07B)(4.73B)(1.59B)
Effect of Forex Changes(29M)(637.97M)(153.84M)(54M)(32.94M)
Net Change in Cash(1.44B)(1.31B)(735.58M)545M(206.06M)
Free Cash Flow5.3B6.75B6.26B3.57B5.82B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.